Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LAUNCH: Lenvatinib in Child-Pugh A and B Advanced Hepatocellular Carcinoma
jRCTs031190017Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of lenvatinib in hepatocellular carcinoma (HCC) (2 arms), sponsored by Eisai Co., Ltd. Primary endpoint: Safety (Adverse Events per CTCAE v4.0). Started Jun 2020; status: completed.
02
Drugs
lenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on jRCTs031190017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031190017.